In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

CD137 is a potent immune costimulatory receptor that promotes T-cell activation and enhances antitumor immune responses. However, systemic activation of CD137 can result in excessive immune ...

Contrary to public concerns, receiving frequent COVID-19 booster vaccinations will not weaken the immune system, providing reassurance to vulnerable groups facing new variants. Study: No evidence of ...